Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab / Richetta, Antonio Giovanni; Elisa, Maiani; Valentina, Carlomagno; Valentina, Carboni; Mattozzi, Carlo; Simona, Giancristoforo; Calvieri, Stefano. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 22:SUPPL. 1(2009), pp. S16-S18. [10.1111/j.1529-8019.2009.01266.x]
Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab
RICHETTA, Antonio Giovanni;MATTOZZI, CARLO;CALVIERI, Stefano
2009
Abstract
Erythrodermic psoriasis is a severe and disabling variant of psoriasis. The authors present the case of a 48-year-old man with psoriasis and hemophilia presented with a history of hepatitis C virus (HCV) infection treated with pegylated interferon alpha-2a and ribavirin therapy. At the end of antiviral therapy, skin manifestation progressively worsened, becoming erythrodermic, with lack of efficacy of steroid therapy. The authors decided to start biological therapy with induction dose of adalimumab (Humira, Abbott Laboratories, Abbott Park, Chicago, IL) 80 mg at Week 0 and 40 mg weekly. In our case, this resulted in a highly effective and safe treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
